A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice
The FASEB Journal · 2024
DOI: 10.1096/fj.202301564rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Panpan Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology, School of Life Science and Technology, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of…. Hauptthemen laut MEDLINE: Hyperlipidemias, Cardiovascular Diseases, Metabolic Diseases, Bacteriophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: National Fund for Major Projects of China, Nation Fund for Major Projects of China, Nation Funder for Major Projects of China.
Abstract (Originalsprache)
Dyslipidemia is characterized by elevated plasma levels of low‐density lipoprotein cholesterol (LDL‐C), triglycerides (TG), and TG‐rich lipoprotein (TGRLs) in circulation, and is closely associated with the incidence and development of cardiovascular disease. Angiopoietin‐like protein 3 (ANGPTL3) deficiency has been identified as a cause of familial combined hypolipidemia in humans, which allows it to be an important therapeutic target for reducing plasma lipids. Here, we report the discovery and characterization of a novel fully human antibody F1519‐D95aA against N‐terminal ANGPTL3 (NT‐ANGPTL3), which potently inhibits NT‐ANGPTL3 with a K D as low as 9.21 nM. In hyperlipidemic mice, F1519‐D95aA shows higher apolipoprotein B (ApoB) and TG‐lowering, and similar LDL‐C reducing activity as compared to positive control Evinacumab (56.50% vs 26.01% decrease in serum ApoB levels, 30.84% vs 25.28% decrease in serum TG levels, 23.32% vs 22.52% decrease in serum LDLC levels, relative to vehicle group). Molecular docking and binding energy calculations reveal that the F1519‐D95aA‐ANGPTL3 complex (10 hydrogen bonds, −65.51 kcal/mol) is more stable than the Evinacumab‐ANGPTL3 complex (4 hydrogen bonds, −63.76 kcal/mol). Importantly, F1519‐D95aA binds to ANGPTL3 with different residues in ANGPTL3 from Evinacumab, suggesting that F1519‐D95aA may be useful for the treatment of patients resistant to Evinacumab. In conclusion, F1519‐D95aA is a novel fully human anti‐NT‐ANGPTL3 antibody with potent plasma ApoB, TG, and LDL‐C lowering activities, which can potentially serve as a therapeutic agent for hyperlipidemia and relevant cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Molecular Biology, School of Life Science and Technology, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University,…
ORCID-Profile: Shuhua Tan
Förderung
- National Fund for Major Projects of China
- Nation Fund for Major Projects of China
- Nation Funder for Major Projects of China
- The Priority Academic Program Development of Jiangsu Higher Education Institutions
- MOST | NSFC | National Fund for Fostering Talents of Basic Science
- China Pharmaceutical University "Double First-Class"
Zitieren
APA
Zhang, P., Wang, K., Hu, T., Xu, M., You, X., Chen, M., Tang, X., Hu, H., Jiang, Y., Zhao, W., & Tan, S. (2024). A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice. The FASEB Journal. https://doi.org/10.1096/fj.202301564rr
Vancouver
Zhang P, Wang K, Hu T, Xu M, You X, Chen M, et al. A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice. The FASEB Journal. 2024. doi:10.1096/fj.202301564rr
BibTeX
@article{Zhang2024,
author = {Zhang, Panpan and Wang, Ke and Hu, Tuo and Xu, Menglong and You, Xiangyan and Chen, Manman and Tang, Xuan and Hu, Huajing and Jiang, Yiwei and Zhao, Wenfeng and Tan, Shuhua},
title = {A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202301564rr}
}
EUVIMED